EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Finerenone, Chronic Obstructive Pulmonary Disease, and Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial

Finerenon, chronisch obstruktive Lungenerkrankung und Herzinsuffizienz mit leicht reduzierter oder erhaltener Ejektionsfraktion: präspezifizierte Analyse der FINEARTS-HF-Studie

Jawad H Butt, Pardeep S Jhund, Alasdair D Henderson, Brian L Claggett, Akshay S Desai, Carolyn S P Lam, Katharina Mueller, Markus F Scheerer, Prabhakar Viswanathan, Michele Senni, Sanjiv J Shah, Adriaan A Voors und 5 weitere

European Journal of Heart Failure · 01.08.2025 · 27 (8) · 1444-1458

DOI: 10.1002/ejhf.3661 ↗

Auf einen Blick

In FINEARTS-HF war der Nutzen von Finerenon gegenüber Placebo bei HFmrEF/HFpEF unabhängig vom COPD-Status konsistent. COPD war mit einem höheren Risiko des primären Endpunkts verbunden.

Fragestellung

Unterscheidet sich die Wirkung von Finerenon gegenüber Placebo bei HFmrEF/HFpEF je nach COPD-Status?

Methode

Präspezifizierte Analyse der FINEARTS-HF-Studie; 6.001 randomisierte Patient:innen mit HFmrEF/HFpEF; COPD-Status investigator-reported; Vergleich Finerenon vs. Placebo.

Ergebnisse

773 Patient:innen (12,9 %) hatten COPD. Primärer Endpunkt bei COPD höher (adjusted RR 1,44; 95 %-KI 1,21–1,71). Finerenon wirkte konsistent: ohne COPD RR 0,84 (95 %-KI 0,73–0,97), mit COPD RR 0,84 (95 %-KI 0,61–1,16); pinteraction = 0,93.

Schlussfolgerung der Autor:innen

Bei HFmrEF/HFpEF waren die günstigen Effekte von Finerenon auf klinische Ereignisse und Symptome unabhängig vom COPD-Status konsistent.

Kernaussagen

  • COPD war mit einem höheren Risiko des primären Endpunkts verbunden.
  • Finerenon senkte den primären Endpunkt in beiden Gruppen ähnlich.
  • Auch die Symptome besserten sich unter Finerenon unabhängig von COPD.

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift European Journal of Heart Failure, online erschienen am 13.04.2025. Verfasst von Jawad H Butt und 16 weiteren Autor:innen. Beteiligte Einrichtung: British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK. Hauptthemen laut MEDLINE: Heart Failure, Naphthyridines, Pulmonary Disease, Chronic Obstructive, Stroke Volume. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Chronic obstructive pulmonary disease (COPD) is associated with worse outcomes in heart failure (HF) with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). A post hoc analysis of TOPCAT suggested that the effectiveness of the steroidal mineralocorticoid receptor antagonist (MRA), spironolactone, may be modified by pulmonary disease, with a greater benefit in patients with COPD/asthma. We examined the effects of the non-steroidal MRA, finerenone, compared to placebo, according to COPD status in a prespecified analysis of FINEARTS-HF. Methods and results A history of COPD was investigator-reported. The primary outcome was the composite of cardiovascular death and total worsening HF events. Of the 6001 patients randomized in FINEARTS-HF, 773 patients (12.9%) had COPD. Compared to patients without COPD, those with COPD had more adverse clinical features, including worse New York Heart Association class and Kansas City Cardiomyopathy Questionnaire (KCCQ) scores, more prior HF hospitalization, atrial fibrillation/flutter, obesity, peripheral artery disease, and hypertension, as well as elevated high-sensitivity troponin T levels. Patients with COPD had a higher risk of the primary endpoint (adjusted rate ratio [RR] 1.44, 95% confidence interval [CI] 1.21–1.71). The benefit of finerenone on the primary outcome was consistent irrespective of COPD status (no COPD: RR 0.84 [95% CI 0.73–0.97]; COPD: 0.84 [95% CI 0.61–1.16]; pinteraction = 0.93). Consistent effects were also observed for all secondary outcomes. Finerenone improved KCCQ total symptom score from baseline to 12 months to a similar extent in patients with and without COPD (pinteraction = 0.46).

Conclusion

In patients with HFmrEF/HFpEF, the beneficial effects of finerenone on clinical events and symptoms were consistent, regardless of COPD status. Clinical Trial Registration: ClinicalTrials.gov ID NCT04435626.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureNaphthyridinesPulmonary Disease, Chronic ObstructiveStroke VolumeAgedFemaleHumansMaleMiddle AgedDouble-Blind MethodMineralocorticoid Receptor AntagonistsTreatment Outcome

Stichwörter der Autor:innen

Chronic obstructive pulmonary diseaseHeart failure with preserved ejection fractionMineralocorticoid receptor antagonist

Substanzen

finerenoneMineralocorticoid Receptor AntagonistsNaphthyridines

Autor:innen und Institutionen

  • British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
  • Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • National Heart Centre Singapore & Duke-National University of Singapore, Singapore, Singapore.
  • Bayer, Research & Development, Pharmaceuticals, Wuppertal, Germany.
  • Bayer, Global Medical Affairs, Berlin, Germany.
  • Bayer, Research & Development, Pharmaceuticals, Whippany, NJ, USA.

Zitieren

APA

Butt, J. H., Jhund, P. S., Henderson, A. D., Claggett, B. L., Desai, A. S., Lam, C. S. P., Mueller, K., Scheerer, M. F., Viswanathan, P., Senni, M., Shah, S. J., Voors, A. A., Zannad, F., Pitt, B., Vaduganathan, M., Solomon, S. D., & McMurray, J. J. V. (2025). Finerenone, Chronic Obstructive Pulmonary Disease, and Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial. European Journal of Heart Failure, 27(8), 1444-1458. https://doi.org/10.1002/ejhf.3661

Vancouver

Butt JH, Jhund PS, Henderson AD, Claggett BL, Desai AS, Lam CSP, et al. Finerenone, Chronic Obstructive Pulmonary Disease, and Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial. European Journal of Heart Failure. 2025;27(8):1444-1458. doi:10.1002/ejhf.3661

BibTeX
@article{Butt2025,
  author = {Butt, Jawad H and Jhund, Pardeep S and Henderson, Alasdair D and Claggett, Brian L and Desai, Akshay S and Lam, Carolyn S P and Mueller, Katharina and Scheerer, Markus F and Viswanathan, Prabhakar and Senni, Michele and Shah, Sanjiv J and Voors, Adriaan A and Zannad, Faiez and Pitt, Bertram and Vaduganathan, Muthiah and Solomon, Scott D and McMurray, John J V},
  title = {Finerenone, Chronic Obstructive Pulmonary Disease, and Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial},
  journal = {European Journal of Heart Failure},
  year = {2025},
  volume = {27},
  number = {8},
  pages = {1444--1458},
  doi = {10.1002/ejhf.3661}
}
Kostenlos starten →